Oral drug combination extends progression-free survival in advanced ER-positive breast cancer

Estrogen-receptor-positive HER-2-negative advanced breast cancer patients had significantly improved progression-free survival when treated with an oral combination regimen consisting of gairdrestrant, a novel, next-generation selective estrogen receptor degrader, and full antagonist, compared to a standard combination approach. These findings from the Phase 3 AVERA breast cancer study are presented today by Dr. Erica Meyer of…

Read More

FCC approves $8 billion Paramount-Skydance merger

The Paramount Global headquarters in New York, US, on Tuesday, Aug. 27, 2024.  Yuki Iwamura | Bloomberg | Getty Images The Federal Communications Commission cleared the way Thursday for an $8 billion merger between Paramount and Skydance Media. The deal, which was announced more than a year ago, includes the CBS broadcast television network, Paramount…

Read More